Business Context and Reporting Period
This Form 8-K Current Report was filed by Humacyte, Inc. on September 15, 2022. The filing primarily addresses corporate governance changes, specifically the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance data.
Material Changes
The material change disclosed in this filing is the appointment of C. Bruce Green to the Board of Directors on September 15, 2022. General Green will serve as a Class I director, subject to election at the 2025 annual meeting of stockholders.
Management Commentary and Compensation
- Background: General Green previously served as the 20th Surgeon General of the U.S. Air Force (2009-2012) and has been a Director and Chief Medical Officer at Deloitte Federal Consulting since 2013.
- Compensation Arrangement: General Green will participate in the standard compensation program for non-employee directors, which includes:
- A $50,000 annual cash retainer (prorated for 2022).
- An option to purchase 13,000 shares of common stock as a newly appointed director.
- An option to purchase 8,500 shares of common stock annually once considered a continuing director.
- Conflicts of Interest: The filing states there are no arrangements regarding his selection and no direct or indirect material interest in existing or proposed transactions requiring disclosure.
Investor Verification Checklist
- Verify the exact number of shares underlying the stock options granted to General Green (13,000 initial, 8,500 annual).
- Confirm the prorated cash retainer amount for the partial year of service in 2022.
- Review the press release dated September 20, 2022 (Exhibit 99.1) for additional context on the appointment.
- Note that this filing does not contain updated financial statements or guidance; refer to the most recent 10-Q or 10-K for financial metrics.